CAS RN: 186692-46-6 | 产品编码: R0207

Roscovitine

纯度/分析方法: >98.0%(HPLC)(qNMR)

别名：

罗斯科维汀
塞利西利
(R)-2-[[6-(苄氨基)-9-异丙基-9H-嘌呤-2-基]氨基]丁-1-醇
Seliciclib
CYC 202
(R)-2-[[6-(Benzylamino)-9-isopropyl-9H-purin-2-yl]amino]butan-1-ol

产品文档：

规格	单价	同一天	2-3个工作日	左侧以上货期	数量	货期信息
20MG	S$204.00	37	0	下单后约3-4周内可以发货		货期预估

* 订购TCI产品，请联系我们的经销商或联系我们。
* TCI会时常优化储存条件，敬请留意。

添加到您的购物车

基本信息

产品编码	R0207
纯度/分析方法	>98.0%(HPLC)(qNMR)
分子式/分子量	C__1__9H__2__6N__6O = 354.46
外观与形状（20°C）	固体
储存温度	冷冻 (-20°C)
储存在惰性气体下	存放于惰性气体之中
应避免的情况	空气,加热
CAS RN	186692-46-6
Reaxys-RN	7694281
MDL编号	MFCD02266401

质量规格/物性

技术规格

Appearance	White to Light yellow powder to crystal
Purity(HPLC)	min. 98.0 area%
Purity(qNMR)	min. 98.0 %
Specific rotation	+50.0 to +56.0 deg(C=1, CHCL3)
NMR	confirm to structure

物性（参考值）

熔点	108 °C
水溶性	不溶
溶解性（可溶于）	丙酮, 乙醇

安全和法规

GHS

References

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5
- L. Meijer, A. Borgne, O. Mulner, J. P. J. Chong, J. J. Blow, N. Inagaki, M. Inagaki, J.-G. Delcros, J.-P. Moulinoux, Eur. J. Biochem. 1997, 243, 527.
Inhibition of Cyclin-Dependent Kinases by Purine Analogues: Crystal Structure of Human cdk2 Complexed with Roscovitine
- W. F. De Azevedo, S. Leclerc, L. Meijer, L. Havlicek, M. Strnad, S.-H. Kim, Eur. J. Biochem. 1997, 243, 518.
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
- S. J. McClue, D. Blake, R. Clarke, A. Cowan, L. Cummings, P. M. Fischer, M. MacKenzie, J. Melville, K. Stewart, S. Wang, N. Zhelev, D. Zheleva, D. P. Lane, Int. J. Cancer 2002, 102, 463.
Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II-Dependent Transcription and Down-regulation of Mcl-1
- D. E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D. P. Lane, S. R. Green, Cancer Res. 2005, 65, 5399.
Roscovitine in cancer and other diseases (a review)
- J. Cicenas, K. Kalyan, A. Sorokinas, E. Stankunas, J. Levy, I. Meskinyte, V. Stankevicius, A. Kaupinis, M. Valius, Ann. Transl. Med. 2015, 3, 135.

应用

Roscovitine: A Cyclin-Dependent Kinase (CDK) Inhibitor

Cyclins and cyclin-dependent kinases (CDKs) are a key component of the regulatory proteins that control the cell cycle. CDK plays a critical role in regulating the cell cycle transition and is primarily involved in the pathogenesis of cancer. Roscovitine (CYC202) is a CDK inhibitor that competes for ATP binding sites on these kinases, thereby reducing tumor growth and inducing cell death. There are reports that roscovitine inhibits CDK1, CDK2, CDK5 and CDK7 and leads to growth arrest and apoptosis of tumor cell lines. Roscovitine does not significantly affect the activity of other protein kinases. Therefore, roscovitine has been used as an anti-mitotic reagent for cell cycle research. (The product is for research purpose only.)